Oral miltefosine treatment in children with visceral leishmaniasis: a brief review

Oral miltefosine treatment in children with visceral leishmaniasis: a brief review

Visceral leishmaniasis (VL) or kala-azar is an infection disease caused by hemiflagellate protozoan parasites (Leishmania donovani) and transmitted to humans by the phlebotomine sandfly. Leishmaniasis is distributed worldwide and 13 million people are estimated to be infected, with about 1.8 million...

Full description

Bibliographic Details
Main Author:	Emilio Palumbo
Format:	Article
Language:	English
Published:	Elsevier
Series:	Brazilian Journal of Infectious Diseases
Subjects:	Miltefosine treatment children Leishmaniasis
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702008000100002&lng=en&tlng=en

Similar Items

Successful treatment of multifocal cutaneous leishmaniasis with miltefosine
by: Bhushan Madke, et al.
Published: (2011-01-01)

Comparing the Effects of Topical Miltefosine and Glucantime in Treatment of Cutaneous Leishmaniasis
by: Ali Asilian, et al.
Published: (2014-03-01)

Post-kala-azar dermal leishmaniasis developing in miltefosine-treated visceral leishmaniasis
by: Sankha Koley, et al.
Published: (2013-01-01)

Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice
by: Ana Angélica Amorim Santarem, et al.
Published: (2014-07-01)

Investigation of in vitro Efficacy of Miltefosine on Chronic Cutaneous Leishmaniasis
by: Varol Tunalı, et al.
Published: (2022-06-01)

Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil
by: Fabio dos Santos Nogueira, et al.
Published: (2019-02-01)

Inefficacy of the association N-methyl glucamine and topical miltefosine in the treatment of experimental cutaneous leishmaniasis by Leishmania (Leishmania) amazonensis
by: R. N. R. Sampaio, et al.
Published: (2007-01-01)

Positive kidney profile of dogs with Leishmania sp. and treated with miltefosine
by: Danillo Brenno de Assis Torres, et al.
Published: (2024-03-01)

A Pilot Randomized Clinical Trial: Oral Miltefosine and Pentavalent Antimonials Associated With Pentoxifylline for the Treatment of American Tegumentary Leishmaniasis
by: Sofia Sales Martins, et al.
Published: (2021-07-01)

Monitoring Cutaneous Leishmaniasis Lesions in Mice Undergoing Topical Miltefosine Treatment
by: Laura Fernanda Neira, et al.
Published: (2023-11-01)

Treatment of visceral leishmaniasis
by: E M Moore, et al.
Published: (2010-01-01)

Efficacy of miltefosine compared with glucantime for the treatment of cutaneous leishmaniasis: a systematic review and meta-analysis
by: Sohrab Iranpour, et al.
Published: (2019-03-01)

Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis
by: Krishna Pandey, et al.
Published: (2020-12-01)

A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis
by: Raimunda Nonata Ribeiro Sampaio, et al.
Published: (2019-03-01)

Complex cutaneous infection by Leishmania mexicana treated with miltefosine
by: Rachel L. Sadowsky, BA, et al.
Published: (2022-11-01)

Miltefosine and Nifuratel Combination: A Promising Therapy for the Treatment of <i>Leishmania donovani</i> Visceral Leishmaniasis
by: Estela Melcon-Fernandez, et al.
Published: (2023-01-01)

A clioquinol-containing Pluronic® F127 polymeric micelle system is effective in the treatment of visceral leishmaniasis in a murine model
by: Tavares Grasiele S.V., et al.
Published: (2020-01-01)

Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial
by: Luciana Mendes, et al.
Published: (2021-02-01)

Safety and Efficacy of miltefosine alone and in combination with sodium stibogluconate and liposomal amphotericin B for the treatment of primary visceral leishmaniasis in East Africa: study protocol for a randomized controlled trial
by: Kinoti Dedan, et al.
Published: (2011-06-01)

Retrospective Long-Term Evaluation of Miltefosine-Allopurinol Treatment in Canine Leishmaniosis
by: Manuela Gizzarelli, et al.
Published: (2023-06-01)

In Vitro Susceptibility to Miltefosine of <i>Leishmania infantum</i> (syn. <i>L.</i> <i>chagasi</i>) Isolates from Different Geographical Areas in Brazil
by: Caroline Ricce Espada, et al.
Published: (2021-06-01)

EVALUATION OF MILTEFOSINE AGAINST LEISHMANIA MAJOR (MRHO/IR/75/ER): IN VITRO AND IN VIVO STUDIES
by: J. Esmaeili, et al.
Published: (2008-06-01)

EVALUATION OF MILTEFOSINE AGAINST LEISHMANIA MAJOR (MRHO/IR/75/ER): IN VITRO AND IN VIVO STUDIES
by: J. Esmaeili, et al.
Published: (2008-06-01)

In vitro and in vivo antileishmanial activity of β-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis
by: Freitas Camila S., et al.
Published: (2021-01-01)

Estudo comparativo entre miltefosina oral e antimoniato de N-metil glucamina parenteral no tratamento da leishmaniose experimental causada por Leishmania (Leishmania) amazonensis Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis
by: Arnoldo Velloso da Costa Filho, et al.
Published: (2008-08-01)

Estimating the proportion of relapse following treatment of Visceral Leishmaniasis: meta-analysis using Infectious Diseases Data Observatory (IDDO) systematic reviewResearch in context
by: Rutuja Chhajed, et al.
Published: (2024-03-01)

Effect of Clindamycin on Intestinal Microbiome and Miltefosine Pharmacology in Hamsters Infected with <i>Leishmania infantum</i>
by: Ana Isabel Olías-Molero, et al.
Published: (2023-02-01)

Changing clinico-epidemiology of post-kala-azar dermal leishmaniasis (PKDL) in India: Results of a survey in four endemic states
by: Suman Saurabh, et al.
Published: (2020-01-01)

Microbial perils of the tropics: A case of cutaneous leishmaniasis in an immigrant from South America
by: Rachel Cowan, et al.
Published: (2023-01-01)

Mitochondrial Proteomics of Antimony and Miltefosine Resistant Leishmania infantum
by: Isabel M. Vincent, et al.
Published: (2015-10-01)

Impact of clinically acquired miltefosine resistance by Leishmania infantum on mouse and sand fly infection
by: Lieselotte Van Bockstal, et al.
Published: (2020-08-01)

3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosineResearch in context
by: Juliana B.T. Carnielli, et al.
Published: (2022-12-01)

Steroid-responsive unilateral keratouveitis following systemic treatment in a patient with human immunodeficiency virus and leishmaniasis
by: Erin Su, et al.
Published: (2023-01-01)

Nanoassemblies from Amphiphilic Sb Complexes Target Infection Sites in Models of Visceral and Cutaneous Leishmaniases
by: Juliane S. Lanza, et al.
Published: (2022-08-01)

Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine
by: Lu Lu, et al.
Published: (2020-12-01)

The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil
by: Eliane de Morais-Teixeira, et al.
Published: (2011-06-01)

Adamantylidene-substituted alkylphosphocholine TCAN26 is more active against Sporothrix schenckii than miltefosine
by: Luana Pereira Borba-Santos, et al.
Published: (2016-01-01)

Monitoring of serum and urinary biomarkers during treatment of canine visceral leishmaniasis
by: Alvaro Felipe de Lima Ruy Dias, et al.
Published: (2020-08-01)

Induction of Apoptosis by Miltefosine in Iranian Strain of Leishmania infantum Promastigotes
by: S Khademvatan, et al.
Published: (2009-06-01)

Induction of Apoptosis by Miltefosine in Iranian Strain of Leishmania infantum Promastigotes
by: R Hadighi, et al.
Published: (2009-05-01)